Wantstats
Company ProfilePremium

Bausch & Lomb Incorporated

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Bausch & Lomb Incorporated - Healthcare showcase

Year Founded & Workforce

1853

20,000 Employees

Industry

Healthcare

Services

Vitamins for General Eye HealthEye Health Supplements
B

Bausch & Lomb Incorporated Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Bausch & Lomb Incorporated Overview

Company Headquarters: New Jersey, US

Founded: 1853

Workforce: 20,000+

Company Working: Bausch & Lomb Incorporated develops, manufactures, and markets eye care products. The company’s products include contact lens and lens care products, such as chemical disinfectants for soft contact lenses, Boston line of products, and prescription pharmaceutical medicines to treat eye conditions such as glaucoma, conjunctivitis, eye allergies, dry eye, and retinal diseases, among others.

Moreover, it also offers contract manufacturing services for sterile and non-sterile solutions, suspensions, ointments, gels, creams, nasals, and injectables. It is headquartered in the US and has additional offices in Argentina, Australia, Austria, Belgium, Bulgaria, Brazil, Canada, China, the Czech Republic/Slovakia, Dubai, France, Germany, Greece, and Hong Kong, among others. Bausch & Lomb Incorporated operates as a subsidiary of Bausch Health Companies Inc.

Strategy

Bausch & Lomb Incorporated's goal is to become a leading, focused pharmaceutical business via the development of novel therapeutic platforms and data science. It focuses on improving its commercial effectiveness in order to better meet the needs of its clients. In order to increase its market share, it also concentrates on product approvals, the purchase and divestment of goods or whole companies, and the establishment of strategic alliances and collaborations. Furthermore, Bausch & Lomb Incorporated has focused its resources on important growth brands and launches, developing next-generation initiatives, and investing in technology platforms while being at the forefront of medication development in novel drugs.

Company Snapshot

$8,601M

Revenue

20,000

Employees

1853

Founded

New Jersey, US

Headquarters

SWOT Analysis

Strengths

  • One of the largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products.
  • Presence in more than 36 countries worldwide
  • High growth in the business
  • Strong presence in the US and Canada
  • Innovative product portfolio
  • Focus on marketing and sales
  • Constitutes a strong distribution network
  • Well established research and development facilities
  • Brand reputation
  • Strong competency in acquisitions

Weaknesses

  • Revenue dependence on the US
  • Management issues and complexities
  • Limited presence in emerging markets
  • Previous controversies and ongoing legal proceedings may negatively affect the company’s image
  • Primary focus on the US market

Opportunities

  • Partnering with local key players
  • Expansion in the range of products
  • Strategic investments in mergers & acquisitions to increase product portfolio
  • New product launches to expand the product portfolio
  • Collaborations and joint ventures

Threats

  • Worsening regulatory environment in the US
  • High competition
  • High price-sensitivity of consumers
  • International business risk

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
October 2019Product LaunchBausch & Lomb Incorporated announced the US launch of PreserVision AREDS 2 Formula minigel eye vitamins. Thus, the company aims to expand its target audience in the US eye health supplements market.
July 2019Product LaunchBausch & Lomb Incorporated announced the US launch of Ocuvite Eye Performance, an eye vitamin supplement formulated with seven vital nutrients that helps strengthen the macula and protects the eye from the stress of sunlight and blue light emitted from digital devices. This new offering was created to meet the changing needs of consumers while further expanding the company’s eye vitamin portfolio.
February 2019Website LaunchBausch & Lomb Incorporated launched SightMatters.com, a new educational online resource for people living with age-related macular degeneration (AMD).
June 2018Product LaunchBausch & Lomb Incorporated introduced Ocuvite Blue Light eye vitamins, a nutritional supplement formulated with lutein and zeaxanthin.
May 2018Product LaunchThe company introduced PreserVision AREDS 2 Formula chewable vitamins, which were designed to meet the growing consumer preference for chewable tablets.
September 2017Product LaunchThe company launched Ocuvite Adult 50+ Formula Minigel daily eye vitamins that help replenish vital nutrients that eyes can lose as they age. With this, the company expanded its product portfolio.

Product Offering

  • BAUSCH & LOMB INCORPORATED
    • Vitamins for General Eye Health
    • Eye Health Supplements

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales fell from USD 8,601 Mn in 2019 to USD 8,434 Mn in 2021.
Bausch & Lomb Incorporated — By Business Segment
Series (USD Mn)201920202021
Sales8,6018,0278,434
R&D Expenditure471452465

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →